stoxline Quote Chart Rank Option Currency Glossary
Eiger BioPharmaceuticals, Inc. (EIGR)
0.3299  -0 (-0.03%)    11-29 09:42
Open: 0.321
High: 0.3299
Volume: 6,368
Pre. Close: 0.33
Low: 0.321
Market Cap: 15(M)
Technical analysis
2023-11-29 9:15:24 AM
Short term     
Mid term     
Targets 6-month :  0.43 1-year :  0.55
Resists First :  0.37 Second :  0.47
Pivot price 0.34
Supports First :  0.2 Second :  0.17
MAs MA(5) :  0.32 MA(20) :  0.33
MA(100) :  0.51 MA(250) :  1.03
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  24.1 D(3) :  26
RSI RSI(14): 49.2
52-week High :  4.61 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ EIGR ] has closed above bottom band by 39.7%. Bollinger Bands are 46.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.34 - 0.34 0.34 - 0.34
Low: 0.27 - 0.27 0.27 - 0.27
Close: 0.33 - 0.33 0.33 - 0.33
Company Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Headline News

Mon, 13 Nov 2023
Cutera Appoints Stephana Patton as Chief Legal Officer - Yahoo Finance

Thu, 09 Nov 2023
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial ... - PR Newswire

Tue, 12 Sep 2023
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda ... - PR Newswire

Mon, 14 Aug 2023
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial ... - PR Newswire

Thu, 29 Jun 2023
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with ... - PR Newswire

Thu, 11 May 2023
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 44 (M)
Shares Float 36 (M)
Held by Insiders 11.7 (%)
Held by Institutions 62.3 (%)
Shares Short 1,070 (K)
Shares Short P.Month 1,160 (K)
Stock Financials
EPS -1.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.04
Profit Margin 0 %
Operating Margin -527.6 %
Return on Assets (ttm) -52.5 %
Return on Equity (ttm) -226 %
Qtrly Rev. Growth -20.3 %
Gross Profit (p.s.) 0.26
Sales Per Share 0.33
EBITDA (p.s.) -1.88
Qtrly Earnings Growth 0 %
Operating Cash Flow -83 (M)
Levered Free Cash Flow -52 (M)
Stock Valuations
PE Ratio -0.17
PEG Ratio 0
Price to Book value -8.26
Price to Sales 0.99
Price to Cash Flow -0.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android